These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7916571)

  • 1. The O-chain of Brucella abortus lipopolysaccharide induces SDS-resistant MHC class II molecules in mouse B cells.
    Escola JM; Moreno E; Chavrier P; Gorvel JP
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1230-6. PubMed ID: 7916571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Brucella abortus lipopolysaccharide macrodomains as mega rafts.
    Lapaque N; Forquet F; de Chastellier C; Mishal Z; Jolly G; Moreno E; Moriyon I; Heuser JE; He HT; Gorvel JP
    Cell Microbiol; 2006 Feb; 8(2):197-206. PubMed ID: 16441431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brucella abortus lipopolysaccharide in murine peritoneal macrophages acts as a down-regulator of T cell activation.
    Forestier C; Deleuil F; Lapaque N; Moreno E; Gorvel JP
    J Immunol; 2000 Nov; 165(9):5202-10. PubMed ID: 11046053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
    Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
    J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
    J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
    Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
    Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes.
    Forestier C; Moreno E; Méresse S; Phalipon A; Olive D; Sansonetti P; Gorvel JP
    Infect Immun; 1999 Aug; 67(8):4048-54. PubMed ID: 10417173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
    Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
    J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules.
    Forquet F; Barois N; Machy P; Trucy J; Zimmermann VS; Leserman L; Davoust J
    J Immunol; 1999 Mar; 162(6):3408-16. PubMed ID: 10092796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
    Lauritzsen GF; Bogen B
    Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotypic residues in the membrane proximal domain of MHC class II beta-chains control activation of CD4+ T cells.
    Sant AJ
    J Immunol; 1993 Jun; 150(12):5299-310. PubMed ID: 8099935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection.
    Aguirre K; Miller S
    Glia; 2002 Aug; 39(2):184-8. PubMed ID: 12112369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th cells and Th2 responses can develop in the absence of MHC class II-CD4 interactions.
    Wack A; Corbella P; Harker N; Roderick K; Norton T; Williams K; Williams O; Kioussis D
    J Immunol; 1999 Aug; 163(3):1162-9. PubMed ID: 10415010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Brucella abortus proteins that induce proliferation and gamma-interferon secretion by CD4+ T cells from Brucella-vaccinated mice and delayed-type hypersensitivity in sensitized guinea pigs.
    Oliveira SC; Harms JS; Banai M; Splitter GA
    Cell Immunol; 1996 Sep; 172(2):262-8. PubMed ID: 8964089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
    Bertolino P; Rabourdin-Combe C
    Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.